No matches

4 search results for: jak inhibitors

Content temporarily unavailable

Differential Effects of Dupilumab and JAK Inhibitors on CCL17 (TARC) in Patients With AD

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares compares the effects of biologics and JAK inhibitors on the biomarker CCL17 (TARC) in atopic dermatitis.

Content temporarily unavailable

European Academy of Allergy and Clinical Immunology (EAACI) 2023 | Hamburg

Presentation highlights from the ADVENT symposium at the EAACI 2023 congress in Hamburg, Germany.

Content temporarily unavailable

ADVENT On Air | First-hand Experience: Expert Insights on the Management of Atopic Hand and Foot Dermatitis

This podcast episode discusses best practices for the diagnosis of atopic dermatitis of the hands and feet, as well as current and emerging treatment options.

Content temporarily unavailable

European Academy of Dermatology and Venereology (EADV) 2023 | Berlin

ADVENT Symposia brought global experts together to explore the latest advances in pediatric atopic dermatitis (AD), the shared and unique drivers of AD, prurigo nodularis (PN), and chronic spontaneous urticaria (CSU), and the pathology and patient management of PN.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: Costa RicaChange country/region